| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,850 | 6,200 | 18.06. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 22,200 | 30 | |||
| 16,000 | 500 | |||
| 15,000 | 15 | |||
| 7,800 | 400 | |||
| 6,200 | 626 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 626 | 5,850 | |||
| 191 | 5,100 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.878 | 0,840 | 1.577 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | 4basebio Plc - Notice of Investor Presentation | 243 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| Mo | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Mo | 4basebio appoints Dr Jeff Coller to advisory board | 2 | Sharecast | ||
| Mo | 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | 126 | GlobeNewswire (Europe) | Dr. Coller,a Bloomberg Distinguished Professor of RNA Biology and Therapeutics, brings deep expertise to accelerate synthetic DNA and mRNA manufacturingDr. Coller's laboratory team has made seminal... ► Artikel lesen | |
| Mo | 4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | 276 | PR Newswire | 4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
PR Newswire
LONDON, United Kingdom, June 15
4basebio... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | BioRestorative Therapies, Inc: BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth | GlobeNewswire (Europe) | Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative... ► Artikel lesen | |
| Do | Prime Medicine, Inc.: Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease | GlobeNewswire (Europe) | -- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America... ► Artikel lesen | |
| Do | EQS-News: Entera Bio: Novo schrieb mit oralem Wegovy Geschichte - könnte Entera der nächste Milliarden-Player werden? | EQS Group (DE) | EQS-News: Entera Bio
/ Schlagwort(e): Sonstiges
Novo schrieb mit oralem Wegovy Geschichte - könnte Entera der nächste Milliarden-Player werden?
18.06.2026 / 20:30 CET/CEST
Für... ► Artikel lesen | |
| Do | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 | GlobeNewswire (Europe) | Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs - Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA... ► Artikel lesen | |
| Do | Moderna, Inc.: Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine | ACCESS Newswire | FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug... ► Artikel lesen |